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Abstract

Objective Several clinical trials of cardiovascular disease
prevention with statins have reported increased risk of
type 2 diabetes (T2DM) with statin therapy. However,
participants in these studies were at relatively low risk
for diabetes. Further, diabetes was often based on selfreport and was not the primary outcome. It is unknown
whether statins similarly modify diabetes risk in higher risk
populations.
Research design and methods During the Diabetes
Prevention Program Outcomes Study (n=3234), the
long-term follow-up to a randomized clinical trial of
interventions to prevent T2DM, incident diabetes was
assessed by annual 75 g oral glucose tolerance testing
and semiannual fasting glucose. Lipid profile was
measured annually, with statin treatment determined by a
participant’s own physician outside of the protocol. Statin
use was assessed at baseline and semiannual visits.
Results At 10 years, the cumulative incidence of statin
initiation prior to diabetes diagnosis was 33%–37% among
the randomized treatment groups (p=0.36). Statin use
was associated with greater diabetes risk irrespective
of treatment group, with pooled HR (95% CI) for incident
diabetes of 1.36 (1.17 to 1.58). This risk was not materially
altered by adjustment for baseline diabetes risk factors
and potential confounders related to indications for statin
therapy.
Conclusions In this population at high risk for diabetes,
we observed significantly higher rates of diabetes with
statin therapy in all three treatment groups. Confounding
by indication for statin use does not appear to explain this
relationship. The effect of statins to increase diabetes risk
appears to extend to populations at high risk for diabetes.
Trial registration number NCT00038727; Results.

Introduction
The health benefits of the 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A reductase inhibitors (‘statin’ medications) are thought to
extend beyond their cholesterol-lowering
properties. Such pleiotropic actions of statins
may include favorable effects on systemic
inflammation, endothelial function and
oxidative stress,1 important mechanisms
involved in the etiology of cardiometabolic

Significance of this study
What is already known about this subject?
►► In observational studies, statin use has been

associated with increased risk for diabetes.
►► Data from randomized statin trials also suggest

incident diabetes is increased.

What are the new findings?
►► In a population at high risk for diabetes in which

incident diabetes was rigorously detected, statin
use remains a diabetes risk factor.
►► Incident diabetes among statin users was
accompanied by a decline in insulin secretion.

How might these results change the focus of
research or clinical practice?
►► Patients at high risk for diabetes should be

monitored during statin therapy.
►► Additional studies are needed to explore the

mechanisms for statin-associated diabetes.

diseases. These effects might be predicted
to reduce diabetes risk; instead, accumulating evidence suggests that the use of statins
may increase the risk of developing type 2
diabetes. Following an initial publication
reporting this observation,2 meta-analyses of
randomized clinical trials of lipid-lowering
with statins have confirmed this effect, and
suggest that statin treatment is associated with
a small increase, approximately 10%–12%, in
the risk of incident diabetes compared with
placebo,3–6 although not all such analyses find
increases in diabetes risk.7
In these cardiovascular disease (CVD)
prevention trials, diabetes was not the
primary outcome, diabetes ascertainment
was not always based on laboratory testing,
and the absolute risk of developing diabetes
was relatively low in the study populations.
These factors may have limited the sensitivity of the evaluations for observing effects
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of statins on diabetes incidence. Diabetogenic effects
of statins may be more important among individuals
with higher risk of diabetes. In a post-hoc analysis of
two of the studies contributing to the meta-analyses,
the elevated risk appeared to be focused on the subset
of study participants who had pre-diabetes based on
elevated glucose readings.8 We therefore conducted an
analysis to evaluate the statin–diabetes association using
data from the Diabetes Prevention Program (DPP),
which studied a cohort of overweight and obese individuals at high risk for diabetes, followed specifically for
incident diabetes.

Methods
The DPP was a randomized clinical trial testing interventions to prevent or delay the development of diabetes
mellitus (DM) among high-risk individuals.9 The 27
clinical centers in the USA recruited 3234 participants of both sexes, approximately 50% of whom were
members of ethnic or racial minority groups and 20%
of whom were ≥60 years old. The eligibility criteria
included ≥25 years of age, body mass index (BMI)
≥24 kg/m2 (≥22 kg/m2 in Asian–Americans), and both
fasting plasma glucose levels of between 95 and 125 mg/
dL and impaired glucose tolerance (IGT) (2-hour 75 g
postload glucose of 140–199 mg/dL). Major exclusions
included a recent myocardial infarction, symptoms of
coronary heart disease, major illness, prior diagnosis of
DM, or treatment with glucose-lowering medications,
use of medications known to impair glucose tolerance
and a triglyceride level ≥600 mg/dL. Eligible participants received standard advice on healthy diet and physical activity, and were randomly assigned to an intensive
lifestyle intervention, metformin or placebo. At the end
of the main trial (mean follow-up 3.2 years), all participants were offered a group-administered version of the
lifestyle intervention and were invited to enroll in the
DPP Outcomes Study (DPPOS).10 During the DPPOS, all
participants were offered quarterly lifestyle sessions, the
former metformin group received open-label metformin
and the former intensive lifestyle group was offered two
additional lifestyle program per year. This report includes
data up to August 31, 2008, with the median follow-up
from randomization to the most recent evaluation being
10.0 years. The protocol was approved by each center’s
institutional review board and all participants provided
written informed consent.
Lipid profiles and blood pressure were measured annually during DPP and DPPOS, and reports were provided
to the participants, including information as to whether
lipid levels had reached recommended treatment targets
as defined by Adult Treatment Panel (ATP) III. Prescriptions for lipid-lowering and antihypertensive medications
were managed by the participant’s own medical provider,
outside of the study protocol.
2

Assessment of statin use
In the DPP and DPPOS, statins use was recorded along
with other concomitant medications based on self-report. This information was collected at baseline and at
each semiannual follow-up visit, based on the question
‘Has the participant taken any prescription medications
within the past 2 weeks?’ Participants were asked to bring
all prescription pill bottles to each visit and drug name
was recorded. Cumulative statin use was defined as the
number of semiannual visits with reported use.
Diagnosis of diabetes
Diabetes diagnosis was the primary endpoint for DPP/
DPPOS. This was determined by an annual 75 g oral
glucose tolerance test or by a semiannual fasting plasma
glucose level with confirmation by a second test, using
the standardized criteria of the American Diabetes Association11 and the WHO.12
Assessment of covariate data
Body weight was measured to the nearest 0.1 kg semiannually. Waist circumference was measured annually in
the standing position, midway between the highest point
of the iliac crest and the lowest point of the costal margin
in the midaxillary line. Semiannual blood pressure measurements were conducted using calibrated anaeroid or
mercury sphygmomanometers by certified clinic staff,
calculated as the average of two readings in seated
participants.13 Data on age, family history of diabetes
and race/ethnicity were based on self-reports. Fasting
plasma glucose, insulin, glycated hemoglobin (HbA1c)
and lipid profiles were measured in the Central Biochemical Laboratory (University of Washington, Seattle, Washington, USA).14 The Insulinogenic Index (I30−I0/Glu30−
Glu0) was used to assess insulin secretion.15
Statistical analyses
Between-group comparisons were performed using the
χ² test of independence for qualitative variables and
using analysis of variance or t-tests for quantitative variables. Triglycerides, which have a highly skewed distribution, were evaluated using the non-parametric KruskalWallis or Wilcoxon tests. For analyses of changes over
time in quantitative measures, we used the normal errors
longitudinal regression model.16 Interaction between
treatment groups and time was assessed to determine if
changes over time varied across treatment groups. Analysis of change from DPP randomization until the analysis closing date was adjusted for the DPP baseline value.
The time to statin initiation was censored at the time of
diabetes diagnosis or at the last visit for those who did not
develop diabetes, and assessed with the use of life-table
methods. Modified product-limit curves for the cumulative incidence of diabetes were compared with the use of
the log-rank test.
Univariate and multivariate Cox proportional hazards
models were used to assess the time-dependent association between statin use and diabetes onset risk. The Wald
BMJ Open Diab Res Care 2017;0:e000438. doi:10.1136/bmjdrc-2017-000438
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Figure 1 Cumulative incidence of statin initiation by
treatment group.

test provided p values and R2 values for individual covariates, and the likelihood ratio test was used to evaluate
contributions of covariates in the combined model. To
facilitate comparisons of contributions across variables,
HRs were reported for convenient increments approximating 1 SD of continuous measure. Models were
run separately for each treatment group, and a test of
heterogeneity was used to evaluate whether an effect
differed across treatment groups. Metabolic variables in
the time-dependent proportional hazards analyses were
entered as values from the visit immediately preceding
diabetes evaluation.
All statistical analyses were performed using SAS
V.9.4 software. All statistical tests conducted were
two-sided and p values less than 0.05 were considered
statistically significant, without adjustment for multiple
testing.
Results
Statin use was infrequent at DPP baseline (~4%), but
increased progressively over the duration of the study.
At 10 years of follow-up, the cumulative incidence of
reported statin use prior to diabetes diagnoses was similar
among the treatment groups, with 35%, 37% and 33% in
the placebo, metformin and lifestyle groups, respectively
(p=0.36) (figure 1). The most commonly used statins
were simvastatin and atorvastatin (40% and 37%, respectively), followed by lovastatin (9%) and pravastatin (8%).
The prevalence of statin use increased over time and was
substantially higher following the diagnosis of diabetes
(online supplementary figure A).
Baseline characteristics of the full study cohort
(n=3234) according to statin use (at any time during DPP
or DPPOS) are shown in table 1. Participants who used
statins were older and more likely to be male, but did not
differ by race/ethnicity. Statin users had modestly higher
baseline fasting plasma glucose (FPG) and HbA1c, and
lower Insulinogenic Index, than non-statin users, biasing
BMJ Open Diab Res Care 2017;0:e000438. doi:10.1136/bmjdrc-2017-000438

these participants toward higher risk for diabetes. Baseline
levels of LDL-cholesterol and triglycerides were higher
in participants who took statins compared with those not
on statins. A history of CVD and hypertension was also
more frequent among statin users. Socioeconomic status
(defined by years of education and income level) did not
differ by reported statin use (data not shown). None of
these variables differed by treatment group assignment.
The HRs for the development of diabetes associated with
prior statin use are shown in table 2 (and online supplementary figure B). We used sequential models that
controlled for demographics (age, sex and race/ethnicity;
model 1); demographics plus baseline diabetes risk
factors (fasting glucose, Insulinogenic Index, 1/fasting
insulin and waist circumference; model 2); and models
for further adjustment for potential confounders related
to indication for statin use (HDL-C, LDL-C, DBP, SBP,
history of CVD, SES and antihypertensive use at the visit
prior to diabetes assessment; model 3). Intervention-related changes in diabetes risk factor levels (1/fasting
insulin, Insulinogenic Index, waist circumference) were
added in model 4, and model 5 represents concurrent
adjustments of model 2 for indications for statin use and
changes in diabetes risk factors. In the placebo group,
the HRs (95% CIs) for diabetes were 1.21 (0.93 to 1.57)
(model 1, demographics), 1.18 (0.90 to 1.54) (model
2, baseline diabetes risk factors) and 1.15 (0.87 to 1.53)
(model 3, indications for statin use). For the metformin
group, the HR in model 1 was 1.33 (1.02 to 1.73), essentially unchanged following adjustment for diabetes risk
factors (model 2), but lost statistical significance with a
modestly lower HR after adjustment for indications for
statin use in model 3 (HR 1.31 (0.99 to 1.73). Among
lifestyle participants, the HR was 1.59 (1.21 to 2.10) in
model 1, essentially unchanged in model 2 (HR 1.53
(1.16 to 2.03)), and (similar to the metformin group)
was modestly attenuated and lost significance after
adjustment for potential statin treatment confounders in
model 3 (HR 1.36 (1.00 to 1.86)) and changes in diabetes
risk factors (model 4). Concurrent adjustment for indications for statin use and updated diabetes risk factors
(model 5) did not substantially alter the HR in any of the
treatment groups. The test of heterogeneity comparing
randomized treatments was not significant in each of
the models, indicating these HRs were not statistically
different across treatment groups. With all three treatment groups combined, the HR associated with statin
use corresponding to model 1 was 1.36 (1.17 to 1.59). We
found no interaction between sex and statin use (or total
statin exposure) on diabetes risk.
We also analyzed diabetes risk in relation to duration of
statin exposure (figure 2), defined as number of semiannual visits with reported statin use. Baseline statin users
(n=141) were excluded from this analysis since duration of use prior to study enrollment was not available.
Longer duration of statin use was significantly associated
with greater diabetes risk in the lifestyle group (HR per
visit with statin use: 1.06 (1.02 to 1.11), p=0.007). In the
3

Downloaded from http://drc.bmj.com/ on October 16, 2017 - Published by group.bmj.com

Cardiovascular and Metabolic Risk
Table 1 Baseline characteristics according to reported statin use at any time during DPP and DPPOS
Placebo

Metformin

Lifestyle

No reported
statin use
(n=614)

Statin use
reported
(n=468)

No reported
statin use
(n=629)

Statin use
reported
(n=444)

No reported
statin use
(n=672)

Statin use
reported
(n=407)

48.4 (10.6)
27% male

52.8 (9.6)*
36% male*

49.2 (10.5)
31% male

53.3 (9.5)*
38% male***

48.8 (11.7)
30% male

53.6 (9.9)*
36% male***

73% female

64% female

69% female

62% female

70% female

64% female

C 52%

C 57%

C 54%

C 59%

C 52%

C 57%

AA 22%

AA 19%

AA 20%

AA 21%

AA 19%

AA 18%

H 16%

H 15%

H 16%

H 14%

H 18%

H 14%

AI 4%

AI 6%

AI 3%

AI 3%

AI 5%

AI 6%

A 6%

A 4%

A 6%

A 3%

A 6%

A 5%

Body mass index
(kg/m2)

34.5 (7)

33.7 (6)

34.2 (7)

33.4 (6)

34.2 (7)

33.4 (6)

Waist (cm)

105 (15)

105 (14)

105 (15)

105 (13)

105 (15)

105 (14)

FPG (mg/dL)

106 (7)

108 (9)*

106 (9)

108 (9)*

105 (7)

108 (9)*

Two-hour glucose 164 (18)
(mg/dL)

166 (16)

164 (16)

166 (18)

164 (16)

166 (18)

Insulinogenic
Index

109 (70, 164)

101 (64, 160)

108 (70, 164)

95 (63, 140)*

109 (68, 170)

95 (65, 140)*

Fasting insulin
(µIU/mL)

24 (17, 33)

25 (16, 33)

24 (16, 35)

23 (17, 33)

23 (16, 34)

24 (16, 33)

HbA1c (%)

5.9 (0.5)

6.0 (0.5)*

5.9 (0.5)

6.0 (0.5)*

5.9 (0.5)

6.0 (0.5)*

LDL-cholesterol
(mg/dL)

116 (31)

139 (35)*

116 (27)

139 (35)*

116 (31)

139 (35)*

HDL-cholesterol
(mg/dL)

46 (12)

43 (12)

46 (12)

46 (12)

46 (12)

46 (12)

Triglycerides (mg/ 142 (97, 186)
dL)

160 (115, 230)*

124 (89, 178)

160 (115, 221)*

124 (88, 186)

160 (115, 221)*

Per cent with
hypertension

23%

34%*

24%

36%*

25%

35%*

Per cent with
history of CVD
Per cent with
family history of
diabetes

0.8%

3.6%*

0.5%

2.5%*

0.9%

1.7%

72%

68%

65%

73%*

70%

69%

Age (years)
Sex
Race/ethnicity

Data are expressed as mean (SD), median (IQR) or per cent as appropriate. Within each treatment group, significant comparisons between
participants who reported statin therapy versus not are noted in bold with asterisk (*) for p<0.001, (**) for p<0.01 and (***) for p<0.05.
Hypertension defined as blood pressure >130/80 mm Hg or use of antihypertensive medication.
A, Asian–American; AA, African–American; AI, American–Indian; C, Caucasian; CVA, cerebrovascular accident; CVD, cardiovascular disease:
DPP, Diabetes Prevention Program; DPPOS, DPP Outcomes Study; FPG, fasting plasma glucose; H, Hispanic; HbA1c, glycated hemoglobin;
HDL, high density liproprotein; LDL, low density lipoprotein; MI, myocardial infarction.

metformin and placebo group, the HRs per visit reported
with statin use were 1.01 (0.96 to 1.06) and for placebo
1.02 (0.97 to 1.07), respectively. Although neither of
these reached statistical significance, the relationship of
duration of exposure with diabetes risk was not statistically different between groups (p=0.26 testing heterogeneity of these relationships across treatment groups).
To assess whether statin potency was related to diabetes
risk, we grouped reported statin use into ‘low potency’
(pravastatin, lovastatin, fluvastatin, 19%) or ‘high potency’
4

(atorvastatin, simvastatin, rosuvastatin, cerivastatin, 81%)
categories. Diabetes risk did not differ by low versus high
potency statins, with HR of 0.96 (0.68 to 1.35), using the
same adjustments in model 5. Information about statin
dose was not available, but statin dose and/or potency
may be reflected in the magnitude of LDL reduction.
We therefore assessed diabetes HR according to change
in LDL-cholesterol, but found no association (data not
shown). There was no apparent effect of statin potency
to modify the effect of statin use on diabetes incidence.
BMJ Open Diab Res Care 2017;0:e000438. doi:10.1136/bmjdrc-2017-000438
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Table 2 HR (95% CI) for diabetes associated with statin use at visit prior to diabetes diagnosis
Adjusted models

Pooled

Placebo

Metformin

Lifestyle

Group p value

Model 1: demographic
Model 2:
1+baseline diabetes risk
factors

1.36 (1.17 to1.59)
1.35 (1.15 to1.57)

1.21 (0.93 to 1.57)
1.18 (0.90 to 1.54)

1.33 (1.02 to 1.73)
1.37 (1.05 to 1.78)

1.59 (1.21 to 2.10)
1.53 (1.16 to 2.03)

0.36
0.41

Model 3:
2+updated statin
confounders

1.27 (1.08 to1.50)

1.15 (0.87 to 1.53)

1.31 (0.99 to 1.73)

1.36 (1.00 to 1.86)

0.71

Model 4:
2+updated diabetes risk
factors
Model 5: dully adjusted

1.27 (1.08 to1.49)

1.19 (0.91 to 1.55)

1.36 (1.04 to 1.76)

1.37 (1.04 to 1.81)

0.71

1.27 (1.08 to1.50)

1.20 (0.90 to 1.59)

1.33 (1.01 to 1.76)

1.43 (1.06 to 1.94)

0.70

Adjusted HRs for updated statin use are noted in bold at significance level of α=0.05 based on the following models: 1: age, sex, and race/
ethnicity; 2: model 1+baseline diabetes risk factors (family history of diabetes, fasting plasma glucose, log Insulinogenic Index, log 1/
fasting insulin, waist); 3: model 2+time-dependent statin treatment confounders (use of antihypertensive medications, diastolic blood
pressure, systolic blood pressure, HDL-cholesterol, and LDL-cholesterol), which were updated until visit prior to statin initiation or diabetes
assessment, plus baseline SES (years of education and household income) and reported history of cardiovascular disease at baseline;
4: model 2+time-dependent diabetes risk factors (log 1/fasting insulin, log Insulinogenic Index, waist) updated until the visit prior to the
assessment of diabetes; 5: model 3+updated diabetes risk factors. Group p value represents the test for heterogeneity of HR among
treatment group.
HDL, high density lipoprotein; LDL, low density lipoprotein; SES, socioeconomic status.

We explored potential mechanisms by which statins
may promote diabetes by analyzing mean change from
baseline in insulin sensitivity (fasting insulin) and insulin

Figure 2 Diabetes hazard rates by number of visits
with reported statin use. The risk of developing diabetes
associated with the duration of exposure to statin therapy
estimated using Cox proportional hazards models. The
symbol on each line indicates the expected hazard rate
for a subject with a number of visits with reported statin
therapy equal to the mean value for the group over the
group-specific range (5th–95th percentile). The risk for
progression to diabetes by number of visits with reported
statin use was calculated for each treatment group with
model 5 from table 2. The number of semiannual visits
with reported statin use significantly predicted progression
to diabetes only in the lifestyle group (p=0.007); this
relationship was not significantly different across the three
groups (heterogeneity p=0.26).
BMJ Open Diab Res Care 2017;0:e000438. doi:10.1136/bmjdrc-2017-000438

secretion (Insulinogenic Index), according to statin use
(table 3). In the active treatment groups, diabetes prevention was associated with favorable reductions in glucose
and weight, and improvements in beta cell function.17 18
Statin use was associated with significantly smaller favorable changes in fasting glucose, 2-hour glucose, HbA1c
and BMI. In the lifestyle group, Insulinogenic Index
declined with statin use, compared with modest increase
without statin use (p=0.013). There were no significant
changes in fasting insulin in any of the groups, and no
apparent pattern of change that would suggest an effect
of statin use on insulin sensitivity. Overall, it appeared
that the statin-treated participants were relatively resistant to the beneficial effects of DPP interventions on
obesity and beta cell function.

Discussion
This report is the first to evaluate the statin–diabetes
association within a randomized clinical trial designed to
carefully ascertain diabetes incidence in subjects at high
risk for diabetes. In this analysis, statin use was associated with a clear increase in diabetes risk in the cohort
as a whole, with point estimates of the HRs suggesting
this risk is increased by close to 30%. This augmented
risk was only modestly attenuated with adjustment for
variables related to the indication for statin treatment,
suggesting that the indications for therapy were not
themselves major contributors to diabetes risk. Participants who were prescribed statins had modestly higher
levels of glucose at baseline, yet this also did not explain
the higher rates of diabetes among statin users. Our
data suggest the statin-associated diabetes risk did not
differ significantly by treatment group, based on a test
5
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Table 3 Mean change from baseline of selected metabolic variables according to use of statins
Placebo
Statin
use
Fasting glucose (mg/
dL)
Two-hour glucose
(mg/dL)
Glycated hemoglobin
(%)
Insulinogenic Index
Fasting insulin (µU/
mL)
Body mass index (kg/
m2)

Metformin
No statin
use
p

Statin
use

Lifestyle
No statin
use
p

Statin
use

No statin
use
p

3.0

1.9

0.04

−0.3

−1.3

0.03

0.8

−0.4

0.007

−2.2

−3.9

0.38

−2.8

−7.3

0.01

−5.6

−10.9

0.001

0.04

−0.01

<0.01

−0.03

−0.09

<0.001

−0.05

−0.11

−0.21

3.83

0.42

−7.45

−3.85

0.44

−8.54

1.66

<0.001
0.01

2.76

2.61

0.83

−1.44

−0.93

0.43

0.64

−0.19

0.16

0.14

0.12

0.84

−0.29

−0.53

0.04

−0.76

−0.92

0.06

Mean changes from baseline are estimated with adjustment for baseline value from mixed models according to use of statin at time of the
assessment with p values to indicate difference by statin therapy within treatment groups. Changes after the development of diabetes were
excluded in the analyses.

of statistical interaction. Nonetheless, the lower point
estimate of the HR in the placebo group could reflect
their more rapid progression to diabetes,9 providing less
opportunity for statin exposure to demonstrably modify
the rate of progression to overt diabetes. It is also possible
that the somewhat higher HRs in the active treatment
groups could reflect a less robust response to the intervention among those with greater baseline diabetes risk,
who were also more likely to receive statin therapy (attenuation in model 4).
The earliest report of a statin–diabetes association19
suggested a protective effect of pravastatin on diabetes
incidence, although diabetes incidence was not determined using standardized criteria. Subsequent statin
trials did not confirm this protective effect, and in the
Justification of the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) statin
treatment was associated with an increase in physician-diagnosed diabetes (relative risk: 1.25; 95% CI 1.05 to 1.49).
In a meta-analysis of six statin trials (including JUPITER),
statin use was again associated with increased diabetes
risk (OR: 1.13; 95% CI 1.03 to 1.23).20 This finding
has subsequently been confirmed by others, including
a large meta-analysis that included seven additional
studies, which together included over 90 000 participants, of whom 4.9% were assigned to statins and 4.5%
were assigned to placebo-developed diabetes (OR: 1.09;
95% CI 1.02 to 1.17).3 Similar HRs for statin-associated
diabetes have been reported by other investigators.5 6 21 22
In the Women’s Health Initiative,21 statin use at baseline was associated with increased risk of self-reported
diabetes during follow-up (HR 1.71 (1.61 to 1.83)).
Further, risk appeared to increase with longer duration
of statin therapy. Similar to our analysis, adjustment for
possible confounders related to statin use attenuated but
did not eliminate the increased risk (adjusted HR 1.48
(1.38 to 1.59)), indicating that the factors leading to
6

statin use were not themselves sufficient to explain the
observed increase in diabetes.
It has been suggested that statins may ‘uncover’ diabetes
in individuals at high risk, which, on a population basis,
could result in modest increase in diabetes risk. In a
post-hoc analysis of the Treat to New Targets and Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering trials, the effects of statins to magnify
diabetes risk were much more strongly evident among
those with pre-diabetes than those without pre-diabetes.8
Similarly, within the JUPITER trial,20 77% of those in
the intervention arm who developed diabetes during
follow-up had impaired fasting glucose at study entry, and
further analysis showed that increased statin-associated
diabetes risk in this study was limited to participants who
had at least one major diabetes risk factor. In an analysis
of three other statin trials, fasting glucose, triglycerides,
BMI and hypertension emerged as baseline clinical
predictors of incident diabetes.23 These observations,
along with the numerically higher estimates of statin-associated HRs observed in our analyses in DPP participants, suggest that the statin effect is more important
among those with pre-existing diabetes risk. Paradoxically, however, variation in baseline diabetes risk factors
failed to explain the further risk associated with statin
therapy in our cohort, and the HR estimate was greatest
among our lifestyle participants, who experienced the
largest study-related reductions in diabetes risk.
The mechanisms contributing to effects of statins to
modify diabetes risk are poorly understood. A number of
studies have assessed changes in insulin sensitivity (mostly
using Homeostasis Model Assessement - insulin resistance (HOMA-IR)) during statin treatment. A meta-analysis by Baker et al showed that statins differ in their effect
on insulin sensitivity in non-diabetic subjects, with simvastatin decreasing insulin sensitivity, pravastatin increasing
sensitivity, and atorvastatin and rosuvastatin showing no
BMJ Open Diab Res Care 2017;0:e000438. doi:10.1136/bmjdrc-2017-000438
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effect.24 In vitro data suggest that some statins may impair
insulin signaling and reduce expression of the insulin-responsive glucose transporter, GLUT-4.25 26 We saw no
evidence of an effect of statins to modify insulin resistance, assessed as fasting insulin concentrations. Statins
have been reported to reduce pancreatic beta cell insulin
secretion in vitro, but the relevance to insulin secretion
in vivo is not known.27 28 A recent report in metformintreated subjects with type 2 diabetes demonstrated a
reduction in insulin secretion (HOMA-β), no effect of
1 year of treatment with atorvastatin or pravastatin on
insulin sensitivity (measured by euglycemic clamp) and
modest deterioration in glycemic control (HbA1c).29
Our data show evidence for greater deterioration in
insulin secretion among statin users, although this was
only statistically demonstrated in subjects randomized
to the lifestyle arm. This pattern is consistent with previously described metabolic changes underlying progression to diabetes among high-risk individuals30 and with
our observation that participants in the DPP/DPPOS
lifestyle arm who progressed to diabetes had a higher
genetic risk score, which largely reflects polymorphisms
related to beta cell functioning.31 Overall, this suggests
an acceleration of typical glycemic deterioration, rather
than a unique or statin-specific mechanism.
The strengths of the current analysis include rigorous
diabetes ascertainment, prolonged follow-up and
updated information about statin use every 6 months.
The main limitation of this analysis is that statin treatment was not randomized or protocol-driven, but was
based on non-study physician assessments of need for
statin treatment based on factors related to CVD risk.
The observed association between statin use and diabetes
risk in this population was not significantly attenuated
after controlling for potential confounders related to
indication for statin use. In addition, statin use was based
on self-report, which could have resulted in some misclassification. Intensity of statin therapy has been reported to
affect diabetes risk,32 33 but since statin dose is not available in our cohort, our ability to assess this is limited.
For individual patients, a potential modest increase in
diabetes risk clearly needs to be balanced against the
consistent and highly significant reductions in myocardial infarction, stroke and cardiovascular death associated with statin treatment. Nonetheless, glucose status
should be monitored and healthy lifestyle behaviors reinforced in high-risk patients who are prescribed statins for
CVD prophylaxis.
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